Payment overview · 2025
General Payments
$107.27
6 reported records · 5 companies
Healthcare provider profile · identity verified
Katie E Combs, APN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MOUNTAIN HOME, AR · NPI 1518155761
Verified facts
What the public records show
CMS Open Payments records show Katie E Combs, APN received $107.27 in general payments during 2025 across 6 reported records.
GlaxoSmithKline, LLC. accounted for 28.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.92 | 28.8% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $26.23 | 24.4% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $18.13 | 16.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.04 | 15.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.95 | 13.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $107.27 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.92 | 2 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $26.23 | 1 | 2025 |
Source payment records
|
|||||
| ELFABRIO Normalized: elfabrio |
Drug | Chiesi USA, Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 101 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
101 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
80 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 531 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 388 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 330 | 83 |
| Lisinopril | Lisinopril | 299 | 75 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 258 | 44 |
| Losartan Potassium | Losartan Potassium | 209 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 198 | 53 |
| Omeprazole | Omeprazole | 190 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 51 |
| Alprazolam | Alprazolam | 180 | 28 |
| Tramadol Hcl | Tramadol Hcl | 158 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 34 |
| Prednisone | Prednisone | 150 | 76 |
| Celecoxib | Celecoxib | 139 | 30 |
| Furosemide | Furosemide | 137 | 40 |
| Meloxicam | Meloxicam | 130 | 37 |
| Metformin Hcl | Metformin Hcl | 130 | 36 |
| Gabapentin | Gabapentin | 126 | 35 |
| Bupropion Xl | Bupropion Hcl | 123 | 23 |
| Trazodone Hcl | Trazodone Hcl | 123 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 116 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 38 |
| Simvastatin | Simvastatin | 105 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 101 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 39 |
| Allopurinol | Allopurinol | 97 | 21 |
| Methylprednisolone | Methylprednisolone | 96 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 26 |
| Eliquis | Apixaban | 84 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 22 |
| Mounjaro | Tirzepatide | 80 | 16 |
| Montelukast Sodium | Montelukast Sodium | 73 | 17 |
| Ozempic | Semaglutide | 71 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 70 | 17 |
| Carvedilol | Carvedilol | 69 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 52 |
| Potassium Chloride | Potassium Chloride | 65 | 15 |
| Atenolol | Atenolol | 64 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 16 |
| Donepezil Hcl | Donepezil Hcl | 61 | 15 |
| Temazepam | Temazepam | 61 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 20 |
| Propranolol Hcl | Propranolol Hcl | 58 | 13 |
| Diazepam | Diazepam | 51 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Clonazepam | Clonazepam | 48 | suppressed |
| Pregabalin | Pregabalin | 47 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 14 |
| Synthroid | Levothyroxine Sodium | 44 | 12 |
| Azithromycin | Azithromycin | 43 | 37 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 23 |
| Fenofibrate | Fenofibrate | 42 | 11 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Finasteride | Finasteride | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Gemtesa | Vibegron | 36 | suppressed |
| Glipizide | Glipizide | 36 | 11 |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 17 |
| Nystatin | Nystatin | 32 | 12 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 19 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Testosterone | Testosterone | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Topiramate | Topiramate | 26 | 11 |
| Cephalexin | Cephalexin | 24 | 23 |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 13 |
| Ramipril | Ramipril | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Sucralfate | Sucralfate | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $107.27 · 6 records | GlaxoSmithKline, LLC. | ELFABRIO, KISUNLA, TRELEGY ELLIPTA, Xhance | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error